![]() The completion of the Human Genome Project in 2003 ushered in. Genomic Health and Biocartis are shooting for launching in 2019, starting in France and Germany. Watch Genomics, Human Behavior, and Social Outcomes: A Discussion for Journalists, with writer Amy Harmon at the New York Times, Melinda Mills, scientist at Oxford, Erik Parens, Hastings Center scholar, and Arbel Harpak, from University of Texas Austin. ![]() Rather than sending samples to Genomic Health's laboratory, local pathology laboratories and hospitals will be able to run the tests directly, which is ideal for continued growth in international markets. In September, Genomic Health announced a partnership with Biocartis to develop an in vitro diagnostic version of its Oncotype DX Breast Recurrence Score test on Biocartis' Idylla platform.The launch of the Oncotype DX AR-V7 Nucleus Detect test, which identifies men with prostate cancer who won't benefit from androgen receptor inhibitors, is progressing and the company has applied for Medicare coverage.Volume continues to outpace revenue growth as the company performs tests without reimbursement, which will hopefully pay off in the long run, working from a larger base once reimbursement is established in the different payers. Revenue would have been up about 5% without the impact of the hurricanes.invasive breast cancer test volume was flat year over year as the company dominates that market. prostate cancer test where volume was up 39% despite the impact of the hurricane. Most of the growth in test volume is coming internationally where volume increased 14% and in U.S.Some of that lost revenue could show up in the fourth quarter as patients reschedule their appointments, but the company said it's hard to know how much. ![]() Without the disruption, management estimates volume would have increased by approximately 7.6%. hurricanes affecting test volume somewhat.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |